Breast Cancer-Derived Microparticles Reduce Cancer Cell Adhesion, an Effect Augmented by Chemotherapy

Dvir Shechter1, Michal Harel2, Abhishek Mukherjee3

  • 1Department of Cell Biology and Cancer Science, Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 3525433, Israel.

Cells
|October 14, 2020
PubMed

Insights

Tumor-derived microparticles (TMPs) from chemotherapy-treated breast cancer cells promote metastasis by reducing cell adhesion. Inhibiting CD44 on TMPs restores cell adhesion, suggesting a therapeutic target for metastatic breast cancer.

Area of Science:

  • Oncology
  • Cell Biology
  • Biochemistry

Background:

  • Tumor cell heterogeneity drives metastasis, but chemotherapy's impact on this process is unclear.
  • Tumor-derived microparticles (TMPs) are implicated in cancer progression, but their role in chemotherapy-induced metastasis is understudied.

Purpose of the Study:

  • To investigate the role of TMPs in mediating the metastatic switch in breast cancer, particularly after chemotherapy.
  • To explore the involvement of CD44 in TMP-mediated promotion of metastasis.

Main Methods:

  • Comparative analysis of TMP shedding from highly metastatic/chemotherapy-treated vs. control breast cancer cells.
  • Assessment of TMP effects on cell adhesion, actin structure, and biomechanical properties.
  • Pharmacological and genetic inhibition of CD44 on TMPs.
  • Analysis of CD44-expressing TMPs in breast cancer patients treated with paclitaxel.

Main Results:

  • Highly metastatic or chemotherapy-treated breast cancer cells shed more TMPs.
  • These TMPs reduce cell adhesion and disrupt actin filaments, promoting cell dissemination.
  • CD44 on TMPs mediates these pro-metastatic effects; inhibiting CD44 restores cell adhesion.
  • Increased CD44-expressing TMPs were observed in patients treated with paclitaxel.

Conclusions:

  • TMPs promote breast cancer metastasis, an effect amplified by chemotherapy.
  • CD44 is a key mediator of chemotherapy-induced TMP pro-metastatic activity.
  • Targeting CD44 on TMPs may offer a strategy to inhibit chemotherapy-enhanced metastasis.

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.4K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.3K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.6K